What is the recommended management of hemolytic‑uremic syndrome, including supportive care, fluid resuscitation, renal replacement therapy, and specific treatment for atypical complement‑mediated HUS?

Management of Hemolytic Uremic Syndrome

Atypical HUS requires immediate complement inhibition with eculizumab or ravulizumab within 4–8 hours of diagnosis, while typical (STEC-associated) HUS is managed with supportive care only. 1

Immediate Diagnostic Differentiation

The first critical step is distinguishing atypical HUS (aHUS) from typical STEC-HUS, because treatment differs fundamentally:

Essential First-Line Laboratory Tests

• Complete blood count with peripheral smear showing schistocytes (>1%), hemoglobin, and platelet count <150,000/mm³ 2, 3
• Hemolysis markers: elevated LDH, reduced/absent haptoglobin, elevated indirect bilirubin, negative direct Coombs test 3, 4
• Renal function panel: creatinine ≥1.5 mg/dL or ≥50% rise from baseline, urinalysis for hematuria and proteinuria 3
• ADAMTS13 activity to exclude thrombotic thrombocytopenic purpura (TTP); activity <10% indicates TTP requiring immediate plasma exchange instead 3, 4
• Stool culture and Shiga toxin PCR to identify STEC infection 2
• Complement studies: C3, C4, CH50, AP50 (though often normal at baseline) 3, 4

Clinical Clues for Differentiation

• Typical HUS: bloody diarrhea preceding HUS by 4–5 days; most common in children <5 years; peak incidence June–September 2, 5
• Atypical HUS: shorter interval between diarrhea and HUS (or simultaneous onset), family history of TMA, or no diarrhea at all 2, 3
• Critical caveat: Up to 50% of aHUS cases may not present with the full triad initially, but at least one laboratory abnormality is always detectable 3

---

Management of Typical (STEC-Associated) HUS

Supportive care is the cornerstone; no specific therapy has proven benefit. 6, 7

Supportive Measures

• Fluid and electrolyte management: maintain optimal hydration for nephroprotection; avoid volume overload 7, 5
• Renal replacement therapy: initiate dialysis when indicated (severe uremia, hyperkalemia, volume overload, acidosis); peritoneal dialysis is first-choice when available 5
• Blood pressure control: aggressive antihypertensive therapy to prevent hypertensive complications 7
• Red blood cell transfusion: only for symptomatic anemia or hemoglobin <7–8 g/dL; transfuse minimum units necessary 4
• Folic acid supplementation: 1 mg daily 4

Critical Interventions to AVOID

• Do NOT give antibiotics during acute STEC infection or HUS, as they may increase Shiga toxin release and worsen outcomes 7, 5
• Do NOT give antimotility agents, narcotics, or NSAIDs 5
• Avoid platelet transfusions unless life-threatening bleeding occurs, as they can worsen microangiopathic thrombosis 4, 6
• Plasma exchange provides no benefit in typical HUS and may cause harm 8

Monitoring During Acute Phase

• Daily monitoring of hemoglobin, platelet count, LDH, creatinine, and electrolytes during days 1–14 3
• Neurological surveillance: 10–20% develop neurologic complications (seizures, altered mental status); obtain neurology consultation, EEG, and brain MRI if symptoms develop 3, 4
• Approximately 46–67% of children with typical HUS require dialysis 7, 5

Long-Term Follow-Up

• All patients require lifelong renal monitoring for proteinuria, hypertension, and declining GFR 5
• One-third develop long-term renal sequelae; risk increases with longer duration of anuria 5
• Overall mortality 1–5% 5

---

Management of Atypical (Complement-Mediated) HUS

This is a medical emergency requiring immediate multidisciplinary team activation and complement inhibition. 1

Immediate Treatment (Within 4–8 Hours)

Complement Inhibition

• Start eculizumab or ravulizumab immediately upon clinical diagnosis; do NOT wait for genetic testing results 1, 4
• Eculizumab and ravulizumab have equivalent efficacy; ravulizumab allows less frequent infusions (every 8 weeks vs. every 2 weeks) 1, 4
• Treatment should continue for at least 6 months 4
• 40–50% of aHUS patients have no identifiable genetic mutation, so absence of mutation does not exclude diagnosis 1

Pre-Treatment Vaccination (or Concurrent if Urgent)

• Administer both quadrivalent meningococcal conjugate vaccine (A, C, W, Y) AND meningococcal B vaccine at least 2 weeks before starting complement inhibition when possible 4
• If treatment cannot be delayed, vaccinate immediately and start therapy 4
• Provide continuous antimicrobial prophylaxis with penicillin (or macrolide if penicillin-allergic) for the entire duration of complement inhibitor therapy 4

Supportive Care (Same as Typical HUS)

• Fluid and electrolyte management 1
• Renal replacement therapy when indicated 1
• Blood pressure control 1
• Red blood cell transfusion for symptomatic anemia (target hemoglobin 7–8 g/dL) 4
• Avoid platelet transfusions unless life-threatening bleeding 4

Genetic Testing and Counseling

• Order next-generation sequencing of complement genes (CFH, CFHR1-5, C3, CD46, CFI, THBD, DGKE, CFB) after treatment initiation 1, 4
• Results guide long-term management and family screening but should never delay treatment 1, 4
• Provide genetic counseling once diagnosis confirmed 4

Monitoring During Treatment

• Daily laboratory monitoring during acute phase: hemoglobin, platelet count (target >150,000/mm³), LDH, creatinine, electrolytes 3, 4
• Continuous surveillance for meningococcal infection (fever, headache, neck stiffness, rash) 4
• Neurological monitoring: clinical exam, EEG, and brain MRI if symptoms develop 3
• Monitor for signs of relapse: clinical presentation, hemolysis markers, proteinuria, microhematuria 1

Discontinuation Considerations

• Eculizumab discontinuation carries 10–20% risk of recurrence with potential for renal failure 1, 2
• Use genetic risk stratification to guide decisions; absence of identified mutations does NOT guarantee low recurrence risk 4
• Thorough assessment of risk factors is essential before discontinuation 1

---

Multidisciplinary Team Composition

aHUS requires a coordinated multidisciplinary approach from presentation through long-term management. 1

The team should include:

• Nephrologist (lead coordinator) 1
• Hematologist 1
• Emergency physician 1
• Intensivist (many patients require ICU admission) 1
• Neurologist 1
• Pediatrician and family pediatrician (for pediatric cases) 1
• Psychologist 1
• Genetic counselor 4

---

Special Populations

Pregnancy-Associated HUS

• Emergence of acute TMA with complete triad during pregnancy mandates urgent eculizumab treatment 3
• Pregnancy is a known trigger for aHUS in genetically predisposed individuals 1

Post-Transplant HUS

• Acute TMA in transplant recipients requires immediate complement inhibition 3
• In post-transplant patients, 13% lack significant platelet reduction and 38% lack significant anemia despite active TMA 3

Pneumococcal HUS

• Usually presents with severe clinical picture: profound hemolytic anemia, respiratory distress, neurological involvement 6
• Higher acute mortality and long-term morbidity compared to STEC-HUS 7
• Management remains supportive; consider early plasmapheresis for life-threatening hemolysis 5

---

Critical Pitfalls to Avoid

• Never delay eculizumab while awaiting genetic results if aHUS is suspected and STEC-HUS excluded 4
• Never start complement inhibition without laboratory-confirmed active TMA (hemolysis + thrombocytopenia + renal injury); unnecessary treatment exposes patients to serious meningococcal infection risk 3, 4
• Never give antibiotics for suspected or confirmed STEC infection 7, 5
• Never assume typical HUS based solely on presence of diarrhea; aHUS can be triggered by infections 2
• Never administer platelet transfusions in HUS unless life-threatening bleeding occurs 4, 6
• Never use plasma exchange for STEC-HUS or drug-induced TMA; it offers no benefit and adds procedural risk 8
• Do not rely on normal complement levels to exclude aHUS; baseline C3/C4/CH50 are often normal 3